2Central Laboratory, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Hainan, China
3Cardiometabolic Center, State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Abstract
Hypertrophic cardiomyopathy (HCM) is a prevalent genetic cardiovascular disease characterized by asymmetric thickening of the left ventricular wall, frequently occurring in families predisposed genetically. While HCM in twins is rare, it presents a unique opportunity to explore the disease’s genetic and epigenetic underpinnings due to the phenotypic heterogeneity observed even among genetically identical individuals. This review collates and analyzes global clinical studies that focus on the twin phenomena in HCM. It explores the genetic foundations of HCM, examines the influence of environmental and epigenetic factors on disease expression, and emphasizes the crucial role of genetic screening in the early and differential diagnosis of HCM. By focusing on twin cases in HCM, this review aims to enhance our understanding of HCM’s complex genetic background, which could lead to more personalized approaches in the management and treatment of this condition, thus drawing significant interest from researchers and clinicians alike.
Highlights
- Twins with hypertrophic cardiomyopathy (HCM) can show significant phenotypic differences despite identical genetics, highlighting non-genetic factors.
- Hypertrophic cardiomyopathy expression involves a complex interplay of genetic predispositions and environmental or epigenetic factors, as evident from twin case studies.
- Genetic screening enhances early HCM diagnosis and personalized treatment by assessing individual risk.
- Twin studies provide insights into the genetic and environmental aspects of HCM, guiding personalized medicine.
Introduction
Cardiomyopathies represent a heterogeneous group of diseases characterized by structural and functional abnormalities of the heart muscle.1 These disorders are associated with high mortality and morbidity rates.2 The classification of cardiomyopathies has evolved over the years, with the American Heart Association (AHA) proposing a classification system in 2006 that categorizes these diseases into primary (genetic, acquired, mixed) and secondary form.1 Common cardiovascular conditions such as valvular heart diseases, hypertension, and congenital heart defects are generally not classified as cardiomyopathies.3 Hypertrophic cardiomyopathy (HCM) is the most common form of genetic cardiomyopathy,4 primarily characterized by asymmetric thickening of the left ventricular wall (
Epidemiology and Diagnosis of Hypertrophic Cardiomyopathy
Epidemiological data indicate that the incidence of HCM is approximately 1 in 500 in the general population,8 but in populations with a family history of the disease, the incidence may rise to as high as 1 in 200.5,
The diagnosis of HCM is exclusionary13 made after ruling out other cardiovascular and metabolic diseases that could cause ventricular wall thickening, associated with mutations in sarcomere protein genes.14 In adults, an echocardiographic or cardiac magnetic resonance (CMR) measurement of the maximum left ventricular wall thickness ≥15 mm at end-diastole, in the absence of other causes of left ventricular hypertrophy, is sufficient for diagnosis.15 If there is a positive family history of HCM or a positive genetic test, a left ventricular wall thickness ≥13 mm is also diagnostic.5,
Hypertrophic cardiomyopathy follows an autosomal dominant inheritance pattern,20 leading to variability in expression and penetrance among affected individuals,21 thus affecting clinical manifestations and disease progression, posing challenges for diagnosis and treatment.22 Clinically, HCM is diverse, ranging from asymptomatic to severe SCD or HF outcomes (
Genetic Background of Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is primarily inherited in an autosomal dominant manner, involving mutations in at least 11 sarcomere protein genes.16,
The Significance of Twins in Hypertrophic Cardiomyopathy Research
Globally, reports on twins with HCM are rare, and the related research is relatively limited,36,
Twin Cases Studies in Research
Hypertrophic cardiomyopathy can exhibit a variety of clinical symptoms, electrocardiogram (ECG) features, morphological changes, and disease progression. Since twins share most or all of their genetic information, the study of twins serves as an ideal natural model to explore the genetic foundations of diseases. Although the molecular mechanisms underlying HCM remain largely undefined, twin studies enhance understanding of how mutations in disease-causing genes are linked to disease phenotypes, as well as the impact of epigenetic and environmental factors.47-
Clinically, HCM manifests variably not only across different individuals but also within the same family.46 Historically, researchers like Maron et al59 have underscored the value of analyzing genetic characteristics in twins to elucidate disease phenotypes. For instance, in a study of middle-aged MZ twins, despite sharing identical genetic information, the twins exhibited a high consistency in clinical presentation and disease progression, suggesting a strong genetic influence.59 Other case also reported a case where twins, despite living in distinct geographical regions of Australia and leading different lifestyles, experienced cardiac arrests at the same age but showed variations in left ventricular hypertrophy, underscoring the significance of genetic factors in such critical outcomes.53 Conversely, Wang et al47 observed that a pair of monozygotic twins carrying the same
In terms of morphology: Numerous studies have demonstrated that twins with HCM often display identical or similar cardiac morphological features,36,
Electrocardiogram is a valuable diagnostic tool for HCM23 and typically identifies abnormalities such as left ventricular hypertrophy, ST-T changes, and pathological Q-waves.70 However, ECG findings in twins with HCM can also display significant variability, even among twins with identical genetic profiles.47,
Although genetics play a pivotal role in the clinical presentation, morphology, and ECG of HCM, the influence of environmental and epigenetic factors is significant, highlighting the complexity of the disease. Twin studies offer crucial insights into the interaction of genetic and non-genetic factors in HCM. A comprehensive assessment of clinical manifestations, ECG, and cardiac morphology in twins with HCM not only facilitates early diagnosis but also improves patient outcomes by preventing disease progression and protecting cardiac function through aggressive management strategies. This comprehensive approach has important clinical implications, especially for genetically susceptible populations, such as twins or those with a family history of HCM.
Role of Genetic Testing
Hypertrophic cardiomyopathy exhibits significant genetic heterogeneity with family history playing a pivotal role in diagnosis.71 In twin studies of HCM, familial clustering is observed in more than 50% of cases,69 complicating the diagnosis, particularly in familial HCM where phenotypic heterogeneity is prominent. For instance, twin studies have demonstrated substantial variations in disease severity and cardiac structural changes between individuals, even among those harboring the same
Given the genetic heterogeneity of HCM, whole genome sequencing (WGS) and whole exome sequencing (WES) have emerged as crucial tools for diagnosing familial HCM or other cases where the underlying genetic cause remains elusive.79 Whole exome sequencing identifies pathogenic gene variants in up to 60% of HCM cases,5 efficiently sequencing all exons to facilitate the discovery of novel genes and deepen our understanding of HCM’s genetic underpinnings. Next-generation sequencing technologies enable high-throughput sequencing of the entire human genome, assessing not only known single-nucleotide variants and insertions/deletions but also transcriptome variants, copy number variants, and complex genomic structural variants, thus, advancing our comprehension of the genetic etiologies of HCM.80-
When HCM is diagnosed in one twin, it is crucial to screen the other twin and additional family members; a positive result necessitates further cardiac morphological evaluation to confirm the HCM diagnosis, with at least annual follow-up recommended as the disease’s presentation may evolve over time.88 Investigating the medical history of other family members, including those not diagnosed with HCM but who may exhibit related symptoms, is essential to construct a comprehensive genetic profile of the disease. An in-depth understanding of the family genetic background enhances the interpretation of twin data, particularly in analyzing the influence of genetic factors on HCM development. Moreover, genetic testing data could be pivotal for developing future preventive screenings and interventions for high-risk family members. A comprehensive assessment of familial HCM will not only lead to a better understanding of the mechanisms of genetic transmission and expression but also to more effective health management and treatment strategies for twin patients and their families.
Treatment of Hypertrophic Cardiomyopathy in Twins
The primary objectives in managing HCM are to alleviate symptoms, reduce cardiac stress, and enhance survival and quality of life. Given the genetic and phenotypic diversity of HCM, including among genetically similar twins, disease manifestations and treatment options can vary, underscoring the need for personalized treatment strategies (
These cases highlight the significance of considering each twin’s unique clinical manifestations, cardiac morphology, and risk factors as well as their genetic susceptibility and environmental influences to devise the most effective personalized treatment plan. With advances in medical technology and deeper insights into the genetic architecture of HCM, future technologies are anticipated to improve diagnostic precision and discover more efficacious treatments, thereby better controlling disease progression and optimizing patient outcomes.
Outlook
Hypertrophic cardiomyopathy is a common hereditary heart disease characterized by polymorphism in clinical manifestations and variability in cardiac morphology and phenotype. Twin studies have elucidated that even among individuals sharing the same genetic background, disease presentations can vary markedly. This phenotypic diversity underscores the intricate interplay between genetic and environmental factors as well as the pivotal role of epigenetic factors in modulating disease expression. By fostering interdisciplinary collaboration that integrates cardiology, genetics, and data science, the complexities of HCM can be more comprehensively understood. A thorough assessment of family history and precise genetic counseling are crucial for developing effective risk assessment and management strategies. Moreover, personalized treatment adjustments tailored to each patient’s specific condition and living environment are key to enhancing treatment outcomes and improving patient quality of life. With ongoing research, particularly in understanding the genetic and environmental determinants of HCM, novel treatment options are anticipated. These advancements are expected to revolutionize the treatment and management of HCM, thereby improving the prognosis and quality of life for individuals with a familial genetic predisposition.
Footnotes
References
- Maron BJ, Towbin JA, Thiene G. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816. https://doi.org/10.1161/CIRCULATIONAHA.106.174287
- Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. https://doi.org/10.1016/j.jacc.2014.05.003
- . Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. 1980;44(6):672-673. https://doi.org/10.1136/hrt.44.6.672
- Elliott P, Andersson B, Arbustini E. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-276. https://doi.org/10.1093/eurheartj/ehm342
- Elliott PM, Anastasakis A, Borger MA. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. https://doi.org/10.1093/eurheartj/ehu284
- Licordari R, Trimarchi G, Teresi L. Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management. J Clin Med. 2023;12(10):-. https://doi.org/10.3390/jcm12103481
- McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121(7):722-730. https://doi.org/10.1161/CIRCRESAHA.117.309711
- Yotti R, Seidman CE, Seidman JG. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies. Annu Rev Genomics Hum Genet. 2019;20():129-153. https://doi.org/10.1146/annurev-genom-083118-015306
- Maron BJ, Desai MY, Nishimura RA. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):390-414. https://doi.org/10.1016/j.jacc.2021.11.021
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. https://doi.org/10.1016/j.jacc.2015.01.019
- Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117(10):1651-1654. https://doi.org/10.1016/j.amjcard.2016.02.044
- Melas M, Beltsios ET, Adamou A, Koumarelas K, McBride KL. Molecular diagnosis of hypertrophic cardiomyopathy (HCM): in the heart of cardiac disease. J Clin Med. 2022;12(1):-. https://doi.org/10.3390/jcm12010225
- Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-375. https://doi.org/10.1016/j.jchf.2018.02.010
- Ommen SR, Mital S, Burke MA. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):3022-3055. https://doi.org/10.1016/j.jacc.2020.08.044
- Gersh BJ, Maron BJ, Bonow RO. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation. Circulation. 2011;124(24):e783-e831. https://doi.org/10.1161/CIR.0b013e318223e2bd
- Alfares AA, Kelly MA, McDermott G. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-888. https://doi.org/10.1038/gim.2014.205
- Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn. 2013;15(2):158-170. https://doi.org/10.1016/j.jmoldx.2012.09.002
- Rickers C, Wilke NM, Jerosch-Herold M. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6):855-861. https://doi.org/10.1161/CIRCULATIONAHA.104.507723
- Silbiger JJ. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights. J Am Soc Echocardiogr. 2016;29(7):622-639. https://doi.org/10.1016/j.echo.2016.03.003
- Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J. 1987;58(3):259-266. https://doi.org/10.1136/hrt.58.3.259
- Epstein ND, Lin HJ, Fananapazir L. Genetic evidence of dissociation (generational skips) of electrical from morphologic forms of hypertrophic cardiomyopathy. Am J Cardiol. 1990;66(5):627-631. https://doi.org/10.1016/0002-9149(90)90492-j
- Harper AR, Parikh VN, Goldfeder RL, Caleshu C, Ashley EA. Delivering clinical grade sequencing and genetic test interpretation for cardiovascular medicine. Circ Cardiovasc Genet. 2017;10(2):-. https://doi.org/10.1161/CIRCGENETICS.116.001221
- Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 2002;11(20):2499-2506. https://doi.org/10.1093/hmg/11.20.2499
- Vermeer AMC, Clur SB, Blom NA, Wilde AAM, Christiaans I. Penetrance of hypertrophic cardiomyopathy in children who are mutation positive. J Pediatr. 2017;188():91-95. https://doi.org/10.1016/j.jpeds.2017.03.033
- Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016;13(11):651-675. https://doi.org/10.1038/nrcardio.2016.140
- Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients with hypertrophic cardiomyopathy Die from?. Am J Cardiol. 2016;117(3):434-435. https://doi.org/10.1016/j.amjcard.2015.11.013
- Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021;18(6):1012-1023. https://doi.org/10.1016/j.hrthm.2021.01.019
- Gersh BJ, Maron BJ, Bonow RO. ACCF/AHA Guideline for the Diagnosis and Treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery. J Am Coll Cardiol. 2011;58(25):e212-e260. https://doi.org/10.1016/j.jacc.2011.06.011
- Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89(6):727-737. https://doi.org/10.1016/j.mayocp.2014.01.025
- Millat G, Bouvagnet P, Chevalier P. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53(5):261-267. https://doi.org/10.1016/j.ejmg.2010.07.007
- Kaski JP, Syrris P, Esteban MTT. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2(5):436-441. https://doi.org/10.1161/CIRCGENETICS.108.821314
- Thomson KL, Ormondroyd E, Harper AR. Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genet Med. 2019;21(7):1576-1584. https://doi.org/10.1038/s41436-018-0375-z
- Lorca R, Gómez J, Martín M. Insights into hypertrophic cardiomyopathy evaluation through follow-up of a founder pathogenic variant. Rev Esp Cardiol (Engl Ed). 2019;72(2):138-144. https://doi.org/10.1016/j.rec.2018.02.009
- Harley A, Orgain ES. Hypertrophic cardiomyopathy with unusual features in a family. Br Heart J. 1971;33(1):55-61. https://doi.org/10.1136/hrt.33.1.55
- Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(3):201-211. https://doi.org/10.1016/j.jacc.2009.02.075
- Ashraf M, Samad F, Jahangir A, Jan MF, Galazka P, Tajik AJ. Hypertrophic cardiomyopathy in identical twins: a case series. Eur Heart J Case Rep. 2023;7(1):ytac452-. https://doi.org/10.1093/ehjcr/ytac452
- Jansweijer JA, van Spaendonck-Zwarts KY, Tanck MWT. Heritability in genetic heart disease: the role of genetic background. Open Heart. 2019;6(1):e000929-. https://doi.org/10.1136/openhrt-2018-000929
- Shur N. The genetics of twinning: from splitting eggs to breaking paradigms. Am J Med Genet C. 2009;151C(2):105-109. https://doi.org/10.1002/ajmg.c.30204
- Hall JG. Twinning. Lancet. 2003;362(9385):735-743. https://doi.org/10.1016/S0140-6736(03)14237-7
- Balasubramanian R, Vuppalapati S, Avanthika C. Epidemiology, genetics and epigenetics of congenital heart diseases in twins. Cureus. 2021;13(8):e17253-. https://doi.org/10.7759/cureus.17253
- Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(suppl):245-254. https://doi.org/10.1038/ng1089
- Boomsma D, Busjahn A, Peltonen L. Classical twin studies and beyond. Nat Rev Genet. 2002;3(11):872-882. https://doi.org/10.1038/nrg932
- Craig JM, Calais-Ferreira L, Umstad MP, Buchwald D. The value of twins for health and medical research: a third of a century of progress. Twin Res Hum Genet. 2020;23(1):8-15. https://doi.org/10.1017/thg.2020.4
- Ji F, Ning F, Duan H. Genetic and environmental influences on cardiovascular disease risk factors: a study of Chinese twin children and adolescents. Twin Res Hum Genet. 2014;17(2):72-79. https://doi.org/10.1017/thg.2014.5
- McGue M, Osler M, Christensen K. Causal inference and observational research: the utility of twins. Perspect Psychol Sci. 2010;5(5):546-556. https://doi.org/10.1177/1745691610383511
- Rodríguez Junquera M, Salgado M, González-Urbistondo F. Different phenotypes in monozygotic twins, carriers of the same pathogenic variant for hypertrophic cardiomyopathy. Life (Basel). 2022;12(9):-. https://doi.org/10.3390/life12091346
- Wang J, Li W, Han Y, Chen Y. Different clinical presentation and tissue characterization in a monozygotic twin pair with MYH7 mutation-related hypertrophic cardiomyopathy. Int Heart J. 2019;60(2):477-481. https://doi.org/10.1536/ihj.18-167
- Kovács A, Molnár AÁ, Celeng C. Hypertrophic cardiomyopathy in a monozygotic twin pair: similarly different. Circ Cardiovasc Imaging. 2016;9(6):-. https://doi.org/10.1161/CIRCIMAGING.116.004794
- Reid JM, Houston AB, Lundmark E. Hypertrophic cardiomyopathy in identical twins. Br Heart J. 1989;62(5):384-388. https://doi.org/10.1136/hrt.62.5.384
- Palka P, Lange A, Burstow DJ. Different presentation of hypertrophic cardiomyopathy in monozygotic twins. Heart. 2003;89(7):751-. https://doi.org/10.1136/heart.89.7.751
- Repetti GG, Kim Y, Pereira AC. Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proc Natl Acad Sci U S A. 2021;118(10):-. https://doi.org/10.1073/pnas.2021717118
- Ko YL, Tang TK, Chen JJ, Hshieh YY, Wu CW, Lien WP. Idiopathic hypertrophic cardiomyopathy in identical twins. Morphological heterogeneity of the left ventricle. Chest. 1992;102(3):783-785. https://doi.org/10.1378/chest.102.3.783
- Goh CY, Asrar ul Haq M, Mutha V, van Gaal WJ. Synchronous cardiac arrest in monozygotic twins with hypertrophic cardiomyopathy--is sudden cardiac death genetically pre-programmed?. BMC Cardiovasc Disord. 2015;15():16-. https://doi.org/10.1186/s12872-015-0007-3
- Zenovich AG, Lesser JR, Hanna CA, Maron BJ. Identical twins with hypertrophic cardiomyopathy and apical aneurysm. Am J Cardiol. 2006;97(7):1109-. https://doi.org/10.1016/j.amjcard.2005.10.059
- Maron BJ, Haas TS, Lesser JR. Images in cardiovascular medicine. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy. Circulation. 2007;115(24):e627-e628. https://doi.org/10.1161/CIRCULATIONAHA.106.680512
- Maron BJ, Casey SA, Almquist AK. Images in cardiovascular medicine. Hypertrophic cardiomyopathy in monozygotic twins. Circulation. 2002;105(18):2229-. https://doi.org/10.1161/01.cir.0000013097.84796.2a
- Littler WA. Twin studies in hypertrophic cardiomyopathy. Br Heart J. 1972;34(11):1147-1151. https://doi.org/10.1136/hrt.34.11.1147
- Wylie L, Ramage A, MacLeod DC. Hypertrophic cardiomyopathy with shared morphology in identical twins: a case report. Scott Med J. 2002;47(3):64-65. https://doi.org/10.1177/003693300204700306
- Maron BJ, Rowin EJ, Arkun K. Adult monozygotic twins with hypertrophic cardiomyopathy and identical disease expression and clinical course. Am J Cardiol. 2020;127():135-138. https://doi.org/10.1016/j.amjcard.2020.04.020
- Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail. 2018;6(5):353-363. https://doi.org/10.1016/j.jchf.2017.09.011
- Araujo AQ, Arteaga E, Mady C. Hypertrophic cardiomyopathy in monozygotic twins. Arq Bras Cardiol. 2004;82(4):396-399. https://doi.org/10.1590/s0066-782x2004000400012
- Rowin EJ, Maron BJ, Maron MS. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications. JACC Cardiovasc Imaging. 2020;13(9):2002-2016. https://doi.org/10.1016/j.jcmg.2019.09.020
- Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 1979;59(4):689-706. https://doi.org/10.1161/01.cir.59.4.689
- Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8(3):545-557. https://doi.org/10.1016/s0735-1097(86)80181-4
- Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35(1):36-44. https://doi.org/10.1016/s0735-1097(99)00492-1
- Agirbasli M, Hamid R, Jennings HS, Tiller GE. Situs inversus with hypertrophic cardiomyopathy in identical twins. Am J Med Genet. 2000;91(5):327-330. https://doi.org/10.1002/(SICI)1096-8628(20000424)91:5<327::AID-AJMG1>3.0.CO;2-S
- Karatzas NB, Hamill J, Sleight P. Hypertrophic cardiomyopathy. Br Heart J. 1968;30(6):826-834. https://doi.org/10.1136/hrt.30.6.826
- Ciampi Q, Olivotto I, Gardini C. Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: the International Stress Echo Registry. Int J Cardiol. 2016;219():331-338. https://doi.org/10.1016/j.ijcard.2016.06.044
- Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-770. https://doi.org/10.1161/CIRCRESAHA.117.311059
- Muresan ID, Agoston-Coldea L. Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging. Heart Fail Rev. 2021;26(5):1023-1036. https://doi.org/10.1007/s10741-020-09931-1
- Braunwald E, Wigle ED. Idiopathic hypertrophic subaortic stenosis. Chest. 1973;64(2):222-224. https://doi.org/10.1378/chest.64.2.222
- Castillo-Fernandez JE, Spector TD, Bell JT. Epigenetics of discordant monozygotic twins: implications for disease. Genome Med. 2014;6(7):60-. https://doi.org/10.1186/s13073-014-0060-z
- Singh SM, Murphy B, O’Reilly R. Epigenetic contributors to the discordance of monozygotic twins. Clin Genet. 2002;62(2):97-103. https://doi.org/10.1034/j.1399-0004.2002.620201.x
- Machin GA. Some causes of genotypic and phenotypic discordance in monozygotic twin pairs. Am J Med Genet. 1996;61(3):216-228. https://doi.org/10.1002/(SICI)1096-8628(19960122)61:3<216::AID-AJMG5>3.0.CO;2-S
- Ommen SR, Mital S, Burke MA. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2020;142(25):e558-e631. https://doi.org/10.1161/CIR.0000000000000937
- Ingles J, Sarina T, Yeates L. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15(12):972-977. https://doi.org/10.1038/gim.2013.44
- Ware SM. Genetics of paediatric cardiomyopathies. Curr Opin Pediatr. 2017;29(5):534-540. https://doi.org/10.1097/MOP.0000000000000533
- Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019;9(12):-. https://doi.org/10.3390/biom9120878
- Sun Y, Ruivenkamp CAL, Hoffer MJV. Next-generation diagnostics: gene panel, exome, or whole genome?. Hum Mutat. 2015;36(6):648-655. https://doi.org/10.1002/humu.22783
- Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9():387-402. https://doi.org/10.1146/annurev.genom.9.081307.164359
- Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801-811. https://doi.org/10.1016/j.humimm.2021.02.012
- Reinartz J, Bruyns E, Lin JZ. Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms. Brief Funct Genomic Proteomic. 2002;1(1):95-104. https://doi.org/10.1093/bfgp/1.1.95
- Wang H, Nettleton D, Ying K. Copy number variation detection using next generation sequencing read counts. BMC Bioinformatics. 2014;15():109-. https://doi.org/10.1186/1471-2105-15-109
- Medvedev P, Stanciu M, Brudno M. Computational methods for discovering structural variation with next-generation sequencing. Nat Methods. 2009;6(11):S13-S20. https://doi.org/10.1038/nmeth.1374
- Miller DT, Lee K, Chung WK. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(8):1381-1390. https://doi.org/10.1038/s41436-021-01172-3
- Lacaze P, Sebra R, Riaz M. Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. NPJ Genom Med. 2021;6(1):51-. https://doi.org/10.1038/s41525-021-00211-x
- Ingles J, Semsarian C. Conveying a probabilistic genetic test result to families with an inherited heart disease. Heart Rhythm. 2014;11(6):1073-1078. https://doi.org/10.1016/j.hrthm.2014.03.017
- Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705-715. https://doi.org/10.1016/j.jacc.2012.02.068
- Ralph-Edwards A, Woo A, McCrindle BW. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129(2):351-358. https://doi.org/10.1016/j.jtcvs.2004.08.047
- . American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. J Thorac Cardiovasc Surg. 2011;142(6):1303-1338. https://doi.org/10.1016/j.jtcvs.2004.08.047